Spectral MD Holdings, Ltd. Notice of Results (8921K)
07 Septiembre 2021 - 1:00AM
UK Regulatory
TIDMSMD
RNS Number : 8921K
Spectral MD Holdings, Ltd.
07 September 2021
Spectral MD Holdings, Ltd
("Spectral MD" or the "Company" or the Group")
Notice of Interim Results
Investor presentation
LONDON, U.K AND DALLAS, TX, U.S - Spectral MD Holdings, Ltd.
(AIM: SMD), a predictive analytics company that develops
proprietary AI algorithms and optical technology for faster and
more accurate treatment decisions in wound care, announces that its
interim results for the six month period ended 30 June 2021 will be
released on Monday, 13 September 2021.
Investor presentation
Wensheng Fan, Chief Executive Officer, and Wan Lung Eng, Chief
Financial Officer, will provide a live presentation relating to the
Company's interim results via the Investor Meet Company platform on
Monday, 13 September at 16:30hrs BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Spectral MD Holdings, Ltd. via:
https://www.investormeetcompany.com/spectral-md-holdings-ltd/register-investor
Investors who already follow Spectral MD Holdings, Ltd. on the
Investor Meet Company platform will automatically be invited.
For further information please contact:
Spectral MD Holdings, Ltd. investors.spectralmd.com
Wensheng Fan, Chief Executive Officer via Walbrook PR
Wan Lung Eng, Chief Financial Officer
SP Angel Corporate Finance LLP (NOMAD Tel: +44 (0) 20 3470 0470
& BROKER)
Stuart Gledhill/ Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Sales & Broking)
Walbrook PR Ltd (Media & Investor Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
Relations)
Paul McManus/Sam Allen Mob: +44 (0)7980 541 893 / +44 (0)7502
Alice Woodings 558 258
+44 (0)7407 804 654
About Spectral MD Holdings, Ltd. ( www.spectralmd.com )
Using its DeepView(R) Wound Imaging Solution, an internally
developed AI technology and multispectral imaging system which has
received FDA Breakthrough Designation for the burn indication,
Spectral MD is able to distinguish between non-healing and healing
human tissue invisible to the naked eye. Spectral MD currently is
able to provide 'Day One' healing assessments for burn wounds and
diabetic foot ulcers (DFU) with other applications being
explored.
Spectral MD has to date received substantial support from the US
government with contracts from institutions such as Biomedical
Advanced Research and Development Authority (BARDA), National
Science Foundation (NSF), National Institute of Health (NIH) and
Defense Health Agency (DHA) in support of the burn application for
its DeepView(R) solution.
The Company has two principal trading subsidiaries, Spectral MD,
Inc. and Spectral MD UK Limited.
DeepView(R)
DeepView(R) is a predictive analytics platform that combines AI
algorithms and advanced optical technology for wound healing
prediction. It is non-invasive, non-radiation, non-laser and does
not require the use of injectable dye. This integration can be
characterised into four distinct components: DeepView(R) imaging,
data extraction, AI model building and AI wound healing
prediction.
-- The DeepView(R) imaging technology consists of patented,
proprietary, multi-spectral optics and sensors that can classify
wound tissue physiology and capture the viability of various
biomarkers within the skin. The imaging technology extracts
appropriate clinical data, processes the image, and displays a
comparison of the original image next to an image with a colour
overlay of the non-healing portions of the wound. The image
acquisition takes 0.2 seconds, and the output takes approximately
20 to 25 seconds.
-- The DeepView(R) data extraction consist of proprietary optics
that are able to extract millions of data points from each raw
image. This information is then used to build and continually
improve the AI model, which is trained and tested against a
proprietary database of more than 66.7 billion pixels with an
ever-growing input of clinically-validated data points.
-- The AI algorithm then produces a predictive wound healing
assessment in the form of an objective, accurate, and immediate
binary wound healing prediction. This prediction is graphically
represented to the clinician through a coloured overlay of the
original image that annotates the non-healing portion of the
wound.
DeepView(R) is designed to allow clinicians to make a more
accurate, timely and informed decision regarding the treatment of
the patient's wound. In the case of DFUs, a non-healing assessment
would provide the physician with the appropriate justification to
use an advanced wound care therapy on 'Day One' as opposed to
waiting 30 days and potentially losing the patient to lack of
patient follow-up or risking patient noncompliance with standard
wound therapy. For burn wounds, the clinician can make an immediate
and objective determination for appropriate candidates for surgery
as well as determining what specific areas of the burn wound will
require skin grafting. DeepView(R)'s current accuracy for burn
wounds is 91 per cent., compared with current physician accuracy of
50 per cent. to 70 per cent. The current clinical accuracy of
DeepView(R) is 83 percent for DFUs. Both of these accuracy
percentages are expected to increase with additional R&D
efforts, including clinical studies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORGZGGLVVGGMZM
(END) Dow Jones Newswires
September 07, 2021 02:00 ET (06:00 GMT)
Spectral Md (LSE:SMD)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Spectral Md (LSE:SMD)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024